20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Phase 3 clinical trial of ambroxol for Parkinson’s confirmed
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
Our 2022 research summary
2022 has seen Cure Parkinson’s emerge from the COVID pandemic with a bumper year of research activity; with clinical trial results being reported and exciting, innovative research projects being awarded funding. We are proud to share this end of year summary of some of these…
STEM-ing the progression of Parkinson’s
An exciting new clinical trial called STEM-PD is due to start in Sweden and the UK which will focus on stem cell transplantation as a potential treatment for Parkinson’s.
Results of FAIRPARK-II deferiprone trial published
The results of the most recent study of deferiprone in people with Parkinson’s (the FAIRPARK-II study) have been published in the New England Journal of Medicine.
Cure Parkinson’s runners head across the pond for the 2022 New York City Marathon
Four inspirational runners joined Team Cure at the New York City Marathon to raise funds for Parkinson’s research. On Sunday 6 November Cure Parkinson’s CEO Will Cook, Nicky Edwards and brother and sister duo Charlie and Jessica Brew all took part in the iconic race,…